| |
|
|
Session 66
Poster Presentations New Antiretrovirals Tuesday 1:30 - 3:30 pm Hall A |
| 550 | Long-term Efficacy and Safety of Emtricitabine in HIV+ Adults Switching from a Lamivudine Containing HAART Regimen C. Wakeford*, G. Shen, L. Hulett, J.B. Quinn, F. Rousseau Triangle Pharm, Inc, Durham, NC |
| 551 | Once-daily Combination of Emtricitabine, Didanosine, and Efavirenz vs Continued PI-based HAART in HIV-infected Adults with Undetectable Plasma HIV-RNA: 48-week Results of a Prospective Randomized Multicenter Trial (ALIZE-ANRS 99). J M Molina*1, F Ferchal1, C Rancinan2, P Yeni3, W Rozenbaum4, V Journot2, L Morand-Joubert5, S Fournier1, P Morlat 6, B Dupont 7, JF Delfraissy8, P Dellamonica9, I Poizot-Martin10, E Rosenthal9, G Chene2 1Hosp St Louis, Paris, France; 2INSERM U330, Bordeaux, France; 3Hosp Bichat, Paris, France; 4Hosp Tenon, Paris, France; 5Hosp St Antoine, Paris, France; 6Hosp de Bordeaux, France; 7Hosp Necker, Paris, France; 8Hosp Kremlin Bicetre, Paris, France; 9Hosp de Nice, Paris, France; and 10Hosp de Marseille, France |
| 552 | Sustained Anti-HIV-1 Effect of Racivir Combined with D4T and Sustiva Following a 14-day Treatment of Infected Volunteers M. J. Otto*1, K. Arastèh2, P. Kreckel2, D. Drauz2, A. Beard1, L. Cartee1, S.J. Hurwitz3, D.C. Liotta4, R.F. Schinazi3, R. L. Murphy5 1Pharmasset, Inc, Tucker, GA; 2Epimed GmbH, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 3Emory Univ Sch Med, and Veterans Affairs Med Ctr, Atlanta, GA; 4Emory Univ, Atlanta, GA; and 5Northwestern Univ, Chicago, IL |
| 553 | TMC114 (UIC96017): A Novel Nonpeptidic Protease Inhibitor Potent Against Multi-PI Resistant HIV In Vitro Y Koh*1, H Nakata1, K Maeda1, JF Kincaid2, G Bilcer2, D Thippeswamy2, AK Ghosh2, H Mitsuya1,3 1Kumamoto Univ Sch of Med, Japan; 2Univ of Illinois at Chicago; and 3Natl Cancer Inst, Bethesda, MD |
| 554 | Preliminary Results of Dosing of Amdoxovir in Treatment-experienced Patients M. Thompson*1, G. Richmond2, H. Kessler3, A. Bae4, J. Sorbel4, N. Sista4, N. Adda4, F. Rousseau4 1Atlanta, GA; 2Fort Lauderdale, FL; 3Chicago, IL; and 4Triangle Pharm, Inc, Durham, NC |
| 555 | Long-term Efficacy and Safety of Atazanavir with Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or ATV: 108-week Results of BMS Study 008/044 R. Murphy*1, V. Pokrovsky2, W. Rozenbaum3, R. Wood4, L. Percival5, L. Odeshoo5, M. Giordano5 1Northwestern Univ, Chicago, IL; 2Fed AIDS Ctr, Moscow, Russia; 3Hosp Tenon, Paris, France; 4Univ of Capetown, South Africa; and 5Bristol-Myers Squibb, Wallingford, CT |
| 556 | Distinct Antiviral Resistance Profiles for the Authentic HIV Integrase Inhibitors; the Diketo Compounds L-708,906 and S-1360 and the Pyranodipyrimidine V-165 V. Fikkert*1, B. Van Maele1, B. Van Remoortel1, M. Michiels1, J. Vercammen2, C. Pannecouque1, Y. Engelborghs2, E. De Clercq1, Z. Debyser1, M. Witvrouw1 1Rega Inst for Med Res, Katholieke Univ Leuven, Belgium and 2Lab for Biomolecular Dynamics, KULeuven, Leuven, Belgium |
| 557 | Analysis of Baseline Enfuvirtide (T20) Susceptibility and Co-receptor Tropism in Two-phase III Study Populations JM Whitcomb1, W Huang1, S Fransen1, T Wrin1, E Paxinos1, J Toma1, M Greenberg2, P Sista2, T Melby2, T Matthews2, R DeMasi2, G Heilek-Snyder3, N Cammack3, N Hellmann1, C Petropoulos*1 1ViroLogic, San Francisco, CA; 2Trimeris, Research Triangle Park, NC; and 3Roche, Palo Alto, CA |
| 558 | Lack of Influence of gp41 Antibodies that Cross-react with Enfuvirtide on the Efficacy and Safety of Enfuvirtide in TORO 1 and TORO 2 Phase III Trials S. Walmsley*1, K. Henry2, C. Katlama3, M. Nelson4, A. Lazzarin5, J. Reynes6, B. Clotet7, M. Salgo8, R. Demasi9, J. Delehanty9 1Univ of Toronto, Canada; 2Hennepin County Med Ctr, Minneapolis, MN; 3Pitié-Salpêtrière Hosp, Paris, France; 4Chelsea and Westminster Hosp, London, UK; 5San Raffaele Sci Inst, Milan, Italy; 6CHU Gui de Chauliac, Montpellier, France; 7IrsiCaixa Fndn, Hosp Germans Trias i Pujol, Barcelona, Spain; 8Hoffmann-La Roche, Inc, Nutley, NJ; and 9Trimeris Inc, Durham, NC |
| 559 | Development of a Novel Fusion Inhibitor, SC34EK: High Susceptibility to HIV Variants Resistant to Fusion Inhibitors In Vitro E. Kodama*, D. Nameki, M. Ikeuchi, A. Otaka, H. Tamamura, N. Fujii, M. Matsuoka Kyoto Univ, Japan |
| 560 | HIV-gp41 Peptides Based on IL-2 Structural Homologies are More Potent Inhibitors of HIV-1 Replication J.D. Mosca*1, M.G. Lewis2, Q. Sattentau3, P.F. Serres1, P.P. McCann1 1Mymetics Corp, Annapolis, MD; 2Southern Res Inst, Frederick, MD; and 3Imperial Coll of Med, Univ of London, UK |
| 561 | Viral Resistance and Pharmacologic Analyses of Phase I/II Study Patients Treated with the HIV-1 Entry Inhibitor PRO 542 W. Olson*1, R. Israel1, J. Jacobson2, L. Vassilatos1, D. Tran1, N. Stambler1, M. Barish1, B. O'Hara1, T. Ketas1, B. Sullivan1, J. Moore3, C. Petropoulos4, P. Maddon1 1Progenics Pharm, Inc, Tarrytown, NY; 2Beth Israel Med Ctr, New York, NY; 3Weill Med Coll of Cornell Univ, New York, NY; and 4ViroLogic, San Francisco, CA |
| 562 | TAK-220, A Novel Small Molecule Inhibitor of CCR5 has Favorable Anti-HIV Interactions with Other Antiretrovirals In Vitro C.L. Tremblay*1, F. Giguel2, J.L. Hicks2, T.C. Chou3, Y. Lizawa4, Y. Sugihara4, M.S. Hirsch2 1CHUM, Montreal, Canada; 2Massachusetts Gen Hosp, Boston; 3Mem Sloan-Kettering Cancer Ctr, New York, NY; and 4Takeda Chemical Industries, Ltd, Osaka, Japan |
| 563 | Anti-HIV Activity Profile of AMD070, an Orally Bioavailable CXCR4 Antagonist H D. Schols*1, S. Claes1, S. Hatse1, K. Princen1, K. Vermeire1, E. De Clercq1, R. Skerlj2, G. Bridger 2, G. Calandra2 1Rega Inst for Med Res, Katholieke Univ Leuven, Belgium and 2AnorMED, Langley, Canada |
| 564 | Biological and Biochemical Characterization of a Highly Polymerized CD4-Ig Fusion Protein that Mediates Efficient Antibody Dependent Cell Mediated Cytotoxicity Against HIV-infected Cells N. S. Gupta*1, T. D.Steenbeke2, D. Van Ryk2, P. Sun3, S. Radaev3, P. Schuck4, D. Mavilio2, S. Kottilil2, M. A. Chaikin2, P. Khazanie2, R. Rabin5, C. Cicala2, J. Arthos2, A. S. Fauci2 1Howard Hughes Med Inst (HHMI)-NIH Res Scholars Prgm, Bethesda, MD; 2Lab of Immunoregulation/NIAID/NIH, Bethesda, MD; 3Natl Inst of Allergy and Infectious Diseases, NIH, Bethesda, MD; 4Office of Dietary Suppl (OD), NIAID, NIH, Bethesda, MD; and 5Ctr for Biologics Eval and Res, FDA, Bethesda, MD |
| 564b | Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results S Staszewski*1, JE Gallant2, AL Pozniak3, JMAH Suleiman4, E DeJesus5, B Lu6, J Sayre6, A Cheng6 1Univ Hosp, J W Goethe-Universität, Frankfurt, Germany; 2Johns Hopkins Univ School of Medicine, Baltimore, MD; 3Chelsea and Westminster Hosp, London, UK; 4Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil; 5IDC Research Initiative, Altamonte Springs, FL; and 6Gilead Scis, Foster City, CA |
| 564a | Potent in vivo anti-R5-HIV effects of AK602, a novel spirodiketopiperazine (SDP)-containing HIV-specific CCR5 inhibitor, in hu-PBMC-NOD-SCID mice H Nakata *1, K Maeda1, Y Kawano 2, T Miyakawa1, S Shibayama 3, M Matsuo 3, Y Takaoka3, Y Koyanagi2, H Mitsuya1,4 1Kumamoto University School of Medicine, Kumamoto,Japan; 2Tohoku University Graduate School of Medicine, Sendai,Japan; 3Ono Pharmaceutical Co LTD, Osaka,Japan; and 4National Cancer Institute, Bethesda, MD |